Company / Cash per Share
GT Biopharma, Inc. Cash per Share History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.29
FY2020
5-year range
$0.00 / $1.29
FY2016-FY2020
Trend
+607.8%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash per Share changed +608% YoY in FY2020, a notable deviation from the 7-year average annual change of +3776%.
Based on SEC 10-K filings.
1.29 in FY2020 with a 5-year CAGR of +134.6%.
Improved from $0.36 to $1.29 over the past 4 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +92.0%
- 5-Year CAGR
- +134.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, cash per share increased 607.8% year-over-year.
- Lowest cash per share in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $1.29 | +607.8% |
| FY2017 | $0.18 | -48.8% |
| FY2016 | $0.36 | +1860.7% |
| FY2015 | $0.02 | +24114.2% |
| FY2014 | $0.00 | -69.5% |
| FY2013 | $0.00 | -28.1% |
| FY2012 | $0.00 | -5.4% |
| FY2011 | $0.00 | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026